Metabolic pathways, together with receptor- and nonreceptor-mediated phenotypic activities of its intermediates, have been identified as a cutaneous melatoninergic system. Pharmacological modulation of melatonin or its metabolites may be used to treat cutaneous disorders and aging.
[Journal of Investigative Dermatology]
